The estimated Net Worth of Paul Blanchfield is at least $14 Million dollars as of 8 August 2024. Mr Blanchfield owns over 2,000 units of Lantheus Inc stock worth over $10,091,011 and over the last 5 years he sold LNTH stock worth over $3,143,331. In addition, he makes $734,545 as Chief Operating Officer at Lantheus Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr Blanchfield LNTH stock SEC Form 4 insiders trading
Mr has made over 14 trades of the Lantheus Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,000 units of LNTH stock worth $192,780 on 8 August 2024.
The largest trade he's ever made was selling 18,023 units of Lantheus Inc stock on 7 March 2024 worth over $1,116,705. On average, Mr trades about 2,197 units every 54 days since 2020. As of 8 August 2024 he still owns at least 98,980 units of Lantheus Inc stock.
You can see the complete history of Mr Blanchfield stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Paul M. Blanchfield biography
Paul M. Blanchfield is the Chief Operating Officer at Lantheus Inc.
What is the salary of Mr Blanchfield?
As the Chief Operating Officer of Lantheus Inc, the total compensation of Mr Blanchfield at Lantheus Inc is $734,545. There are 7 executives at Lantheus Inc getting paid more, with Mary Heino having the highest compensation of $4,320,910.
How old is Mr Blanchfield?
Mr Blanchfield is 40, he's been the Chief Operating Officer of Lantheus Inc since . There are 25 older and 1 younger executives at Lantheus Inc. The oldest executive at Lantheus Holdings Inc is James Thrall, 76, who is the Independent Director.
What's Mr Blanchfield's mailing address?
Paul's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON ROAD, SOUTH BUILDING, BEDFORD, MA, 01730.
Insiders trading at Lantheus Inc
Over the last 9 years, insiders at Lantheus Inc have traded over $500,725,766 worth of Lantheus Inc stock and bought 8,000 units worth $141,200 . The most active insiders traders include David F Burgstahler, Capital Partners Gp, Llc Av..., and Sriram Venkataraman. On average, Lantheus Inc executives and independent directors trade stock every 11 days with the average trade being worth of $15,777,680. The most recent stock trade was executed by James H Thrall on 21 August 2024, trading 1,000 units of LNTH stock currently worth $98,520.
What does Lantheus Inc do?
lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.
What does Lantheus Inc's logo look like?
Complete history of Mr Blanchfield stock trades at Lantheus Inc
Lantheus Inc executives and stock owners
Lantheus Inc executives and other stock owners filed with the SEC include:
-
Mary Heino,
President, Chief Executive Officer, Director -
Robert Marshall,
Chief Financial Officer, Treasurer -
Mary Anne Heino,
CEO, Pres & Director -
Michael Duffy,
Senior Vice President, Law and Public Policy and General Counsel -
John Bolla,
Chief Operating Officer, Senior Vice President, Technical Operations -
Simon Robinson,
Senior Vice President - Research and Pharmaceutical Development -
Robert J. Marshall Jr., CFA,
CFO & Treasurer -
Paul M. Blanchfield,
Chief Operating Officer -
Daniel M. Niedzwiecki,
Sr. VP, Gen. Counsel & Corp. Sec. -
Brian Markison,
Non-Executive Independent Chairman of the board -
Samuel Leno,
Independent Director -
Frederick Robertson,
Independent Director -
James Clemmer,
Independent Director -
Gary Pruden,
Independent Director -
Julie McHugh,
Independent Director -
James Thrall,
Independent Director -
Heinz Maeusli,
Independent Director -
Gerard Ber,
Independent Director -
Istvan Molnar,
Chief Medical Officer -
Paul Blanchfield,
Chief Commercial Officer -
Carol Walker,
Senior Vice President - Quality -
Etienne Montagut,
Senior Vice President - Corporate Development -
Etienne Montagut,
Chief Bus. Officer -
Carol Walker,
Sr. VP of Quality -
Ying Yao,
Chief HR Officer -
Melissa Downs,
Director of Corp. Communications -
Linda S. Lennox,
VP of Corp. Communications & Chief of Staff -
Mark Richard Kinarney,
Sr. Director of Investor Relations -
Andrea Sabens,
Principal Accounting Officer -
Capital Partners Gp, Llc Av...,
-
David F Burgstahler,
Director -
Cesare Orlandi,
Chief Medical Officer -
Derace L Schaffer,
Director -
Sriram Venkataraman,
Director -
Timothy G Healey,
SVP, Commercial -
Daniel Niedzwiecki,
See Remarks -
Ying Vivian Yao,
Chief Human Resources Officer -
Minnie Baylor Henry,
-
Andrea Sabens,
Chief Accounting Officer -
Kenneth Pucel,
Director -
John W. Crowley,
VP Finance and Accounting -
John K Bakewell,
CFO and Treasurer -
Patrick O'neill,
Director -
William C. Jr. Dawes,
VP Mfrg and Operations -
Jeffrey Allen Bailey,
CEO and President -
Kimberly Brown,
Chief Accounting Officer -
Jeffrey Humphrey,
Chief Medical Officer -
Sam R Leno,
-
Jean Claude Provost,
Chief Medical Officer